CreativitySafety & Risk ManagementLSD

Adverse Reactions to Psychedelic Drugs - A Review of the Literature

This literature review (1984) examines the basic pharmacology and potential adverse effects of synthetic psychedelics, primarily LSD. It concludes that while acute adverse reactions occur, there is little evidence for organic brain damage or permanent negative changes in personality among users.

Authors

  • Rick Strassman

Published

Journal of Nervous and Mental Disease
meta Study

Abstract

The use of naturally occurring and synthetically derived compounds for their psychedelic effects has been a part of human culture for thousands of years. The basic pharmacology of the major synthetic psychedelic compounds primarily lysergic acid diethylamide [LSD] is described and reference is made to their potentially beneficial psychological effects. Adverse reactions, defined as dysphoric and/or maladaptive/dysfunctional responses to the use of these drugs, sometimes require careful clinical judgment in order to diagnose. These reactions can be effectively classified along a temporal continuum, Acute, short-lived reactions are often fairly benign, whereas chronic, unremitting courses carry a poor prognosis. Delayed, intermittent phenomena flashbacks and LSD-precipitated functional disorders that usually respond treatment appropriate for the non-psychedelic-precipitated illnesses they resemble, round out this temporal means of classification, The question of organic brain damage as well as permanent changes in personality, attitudes, and creativity in patients and normals who have repeatedly ingested psychedelic drugs is controversial, but tends to point to subtle or nonsignificant changes. Future areas for study of the psychedelics’ pharmacological, psychological, and. therapeutic effects are suggested.

Available with Blossom Pro

Research Summary of 'Adverse Reactions to Psychedelic Drugs - A Review of the Literature'

Introduction

Abraham frames psychedelic use as a long-standing human practice and reviews the pharmacology and reported psychological effects of major synthetic psychedelics, with LSD-25 treated as the prototypical compound. Earlier therapeutic enthusiasm in the 1950s–60s is noted alongside growing public and legislative concern about adverse acute and chronic effects; the paper focuses on adverse reactions—defined as dysphoric and/or maladaptive responses—that sometimes require clinical judgement to diagnose. The review sets out to classify and summarise the literature on adverse reactions to psychedelics, to identify methodological problems in existing reports, and to suggest priorities for future research. Abraham seeks to place adverse events on a temporal continuum (acute, delayed/intermittent, chronic) and to examine evidence about etiologies, incidence, clinical management, and long-term sequelae, emphasising the limitations of the available data.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (1)

Papers cited by this study that are also in Blossom

LSD-assisted psychotherapy in patients with terminal cancer

Grof, S., Goodman, L. E., Richards, W. A. · Pharmacopsychiatry (1973)

Cited By (87)

Papers in Blossom that reference this study

Treatment approaches and efficacy in Psychedelic-Induced Psychosis: A systematic review

Sulstarova, A., Scheuerlein, L., Monari, S. et al. · Asian Journal of Psychiatry (2025)

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

Hinkle, J. T., Graziosi, M., Nayak, S. et al. · JAMA Psychiatry (2024)

84 cited
Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users

Fonseca, A. M., Dos Santos, R. G., Santos, F. P. et al. · European Archives of Psychiatry and Clinical Neuroscience (2024)

Psychiatric risks for worsened mental health after psychedelic use

Marrocu, A., Kettner, H., Weiss, B. et al. · Journal of Psychopharmacology (2024)

41 cited
Drug-drug interactions involving classic psychedelics: A systematic review

Halman, A., Kong, G., Sarris, J. et al. · Journal of Psychopharmacology (2023)

40 cited
Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample

Kvam, T-M., Uthaug, M. V., Andersen, K. A. A. et al. · Frontiers in Psychiatry (2023)

17 cited
Psychedelic use and psychiatric risks

Simonsson, O., Goldberg, S. B., Chambers, R. et al. · Psychopharmacology (2023)

Case analysis of long-term negative psychological responses to psychedelics

Bremler, R., Katati, N., Shergill, P. et al. · Scientific Reports (2023)

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Zeifman, R. J., Kettner, H., Pagni, B. A. et al. · Scientific Reports (2023)

22 cited
Show all 87 papers
Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review

Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)

4 cited
Self-reported effects of classic psychedelics on stuttering

Gold, N. D., Goldway, N., Gerlach-Houck, H. et al. · Biorxiv (2023)

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics

Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Journal of Affective Disorders (2023)

Psychedelics and psychological strengths

Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)

Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences

Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)

Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention and treatment

Doyle, M. A., Ling, S., Lui, L. M. W. et al. · Expert Opinion on Drug Safety (2022)

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2022)

Toward a positive psychology of psychoactive drug use

Arnaud, K. O. S. · Drugs Education Prevention and Policy (2021)

Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs

Yaden, D. B., Berghella, A. P., Regier, P. S. et al. · International Journal of Drug Policy (2021)

41 cited
Psychedelics, sociality, and human evolution

Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)

Neuropsychological Functioning in Users of Serotonergic Psychedelics - A Systematic Review and Meta-Analysis

Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)

Use of psilocybin (“mushrooms”) among US adults: 2015-2018

Yockey, R. A., King, K. A. · Journal of Psychedelic Studies (2021)

Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences

Gashi, L., Sandberg, S., Pedersen, W. · International Journal of Drug Policy (2021)

The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

Pivotal Mental States

Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)

Psychedelics as a Novel Approach to Treating Autoimmune Conditions

Thompson, C., Szabo, A. · Immunology Letters (2020)

Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland

Kangaslampi, S., Hausen, A., Rauteenmaa, T. · Journal of Psychoactive Drugs (2020)

Chronic pain and psychedelics: a review and proposed mechanism of action

Castellanos, J. P., Woolley, C., Bruno, K. A. et al. · Regional Anesthesia and Pain Medicine (2020)

101 cited
73 cited
Dissolving the self: Active inference, psychedelics, and ego-dissolution

Deane, G. · Philosophy and the Mind Sciences (2020)

Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)

Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat

Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)

126 cited
Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Felix, M., Stefan, B. · Swiss Medical Weekly (2019)

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)

A Survey of American Psychiatrists’ Attitudes Toward Classic Hallucinogens

Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)

Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)

Nichols, D. E. · ACS Chemical Neuroscience (2018)

Is LSD toxic?

Nichols, D. E., Grob, C. S. · Forensic Science International (2018)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

Psychiatry & the psychedelic drugs. Past, present & future

Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)

Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report

Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Journal of Psychedelic Studies (2017)

6 cited
Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies

Dos Santos, R. G., Hallak, J. E., Bouso, J. C. · Therapeutic Advances in Psychopharmacology (2017)

Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

Halberstadt, A. L. · Current Topics in Behavioral Neurosciences (2017)

116 cited
Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)

Psychedelics in the treatment of unipolar mood disorders: a systematic review

Rucker, J., Young, A. H., Jelen, L. A. et al. · Journal of Psychopharmacology (2016)

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)

Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Lysergic acid diethylamide: a drug of ‘use’?

Das, S., Barnwal, P., Ramasamy, A. et al. · Therapeutic Advances in Psychopharmacology (2016)

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

The Heffter Research Institute: Past and Hopeful Future

Nichols, D. E. · Journal of Psychoactive Drugs (2014)

16 cited
Psilocybin - Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)

The pharmacology of lysergic acid diethylamide: a review

Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members

Santos, R. G., Landeira-Fernandez, J., Strassman, R. J. et al. · Journal of Ethnopharmacology (2007)

Hallucinogens

Nichols, D. E. · Pharmacology and Therapeutics (2004)

Hallucinogen persisting perception disorder: what do we know after 50 years?

Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)

204 cited
Do hallucinogens cause residual neuropsychological toxicity?

Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (1999)

71 cited
Hallucinogens, Serotonin and Obsessive-Compulsive Disorder

Delgado, P. L., Moreno, F. A. · Journal of Psychoactive Drugs (1998)

61 cited
Psychedelic Effects of Ketamine in Healthy Volunteers: Relationship to Steady-state Plasma Concentrations

Bowdle, A. T., Radant, A. D., Cowley, D. S. et al. · Anesthesiology (1998)

527 cited
Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects

Strassman, R. J. · Journal of Nervous and Mental Disease (1995)

93 cited
Dose-response study of N,N-dimethyltryptamine in humans: subjective effects and preliminary results of a new rating scale

Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. et al. · JAMA Psychiatry (1994)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.